Related Experiment Video
Updated: Jun 20, 2026
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
ERBB2 (HER2) protein expression in uterine sarcomas
M Zafrakas1, L Zepiridis, T D Theodoridis
11st Department of Obstetrics & Gynecology, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Greece. mzafrakas@gmail.com
Purpose:
Multiple clinical trials in recent years have shown that breast cancer patients with primary tumors overexpressing ERBB2 can be effectively treated with specific forms of modern anti-ERBB2-targeted therapy. The aim of the present study was to analyze the expression of the ERBB2 (HER2) protein in uterine sarcomas, in order to investigate the possibility of applying this treatment modality in uterine sarcomas.
Methods:
The expression of ERBB2 has been analyzed immunohistochemically in formalin-fixed paraffin-embedded primary uterine sarcomas (n = 11).
Results:
Using a semi-quantitative immunohistochemical score, we found that ERBB2 expression was very weak in the majority of tumors, with only three sarcomas showing moderate ERBB2 expression. Published studies evaluating the same issue in small numbers of uterine sarcomas reached similar findings.
Conclusion:
Overall, ERBB2 expression appears to be weak in uterine sarcomas. However, targeted treatment might still be feasible in a subgroup of patients with uterine sarcomas overexpressing ERBB2.
Insights
ERBB2 (HER2) protein expression is generally weak in uterine sarcomas. However, a subset of patients may benefit from targeted anti-ERBB2 therapy, warranting further investigation.
Area of Science:
- Oncology
- Molecular Biology
- Pathology
Background:
- Targeted therapies against ERBB2 (HER2) protein have shown efficacy in ERBB2-overexpressing breast cancers.
- Uterine sarcomas are rare malignant tumors of the uterus.
Purpose of the Study:
- To investigate the expression levels of ERBB2 (HER2) protein in uterine sarcomas.
- To determine the potential for anti-ERBB2 targeted therapy in uterine sarcoma patients.
Main Methods:
- Immunohistochemical analysis of ERBB2 expression.
- Study included formalin-fixed paraffin-embedded primary uterine sarcoma samples (n=11).
Main Results:
- The majority of uterine sarcomas exhibited very weak ERBB2 expression.
- Three out of eleven sarcomas showed moderate ERBB2 expression.
- Findings align with previous smaller studies on ERBB2 in uterine sarcomas.
Conclusions:
- ERBB2 (HER2) protein expression is predominantly low in uterine sarcomas.
- Targeted anti-ERBB2 therapy may be a viable option for a specific subgroup of uterine sarcoma patients with ERBB2 overexpression.
More Related Videos
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
07:31A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:38Mitogens and the Cell Cycle